581 related articles for article (PubMed ID: 30027399)
1. Does Late Levodopa Administration Delay the Development of Dyskinesia in Patients with De Novo Parkinson's Disease?
Chung SJ; Yoo HS; Lee HS; Jeong HE; Kim SJ; Oh JS; Kim JS; Sohn YH; Lee PH
CNS Drugs; 2018 Oct; 32(10):971-979. PubMed ID: 30027399
[TBL] [Abstract][Full Text] [Related]
2. Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson's disease.
Warren Olanow C; Kieburtz K; Rascol O; Poewe W; Schapira AH; Emre M; Nissinen H; Leinonen M; Stocchi F;
Mov Disord; 2013 Jul; 28(8):1064-71. PubMed ID: 23630119
[TBL] [Abstract][Full Text] [Related]
3. Presynaptic dopamine depletion predicts levodopa-induced dyskinesia in de novo Parkinson disease.
Hong JY; Oh JS; Lee I; Sunwoo MK; Ham JH; Lee JE; Sohn YH; Kim JS; Lee PH
Neurology; 2014 May; 82(18):1597-604. PubMed ID: 24719485
[TBL] [Abstract][Full Text] [Related]
4. Beneficial effects of dipeptidyl peptidase-4 inhibitors in diabetic Parkinson's disease.
Jeong SH; Chung SJ; Yoo HS; Hong N; Jung JH; Baik K; Lee YH; Sohn YH; Lee PH
Brain; 2021 May; 144(4):1127-1137. PubMed ID: 33895825
[TBL] [Abstract][Full Text] [Related]
5. Low-dose levodopa therapy in Japanese patients with Parkinson's disease: a retrospective study.
Kitagawa M; Tashiro K
Intern Med; 2005 Sep; 44(9):939-43. PubMed ID: 16258207
[TBL] [Abstract][Full Text] [Related]
6. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study.
Bracco F; Battaglia A; Chouza C; Dupont E; Gershanik O; Marti Masso JF; Montastruc JL;
CNS Drugs; 2004; 18(11):733-46. PubMed ID: 15330687
[TBL] [Abstract][Full Text] [Related]
7. Risk of Disabling Response Fluctuations and Dyskinesias for Dopamine Agonists Versus Levodopa in Parkinson's Disease.
Haaxma CA; Horstink MW; Zijlmans JC; Lemmens WA; Bloem BR; Borm GF
J Parkinsons Dis; 2015; 5(4):847-53. PubMed ID: 26444087
[TBL] [Abstract][Full Text] [Related]
8. AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study.
Stocchi F; Rascol O; Destee A; Hattori N; Hauser RA; Lang AE; Poewe W; Stacy M; Tolosa E; Gao H; Nagel J; Merschhemke M; Graf A; Kenney C; Trenkwalder C
Mov Disord; 2013 Nov; 28(13):1838-46. PubMed ID: 23853029
[TBL] [Abstract][Full Text] [Related]
9. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa.
Rascol O; Brooks DJ; Korczyn AD; De Deyn PP; Clarke CE; Lang AE
N Engl J Med; 2000 May; 342(20):1484-91. PubMed ID: 10816186
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the efficacy of pramipexole for treating levodopa-induced dyskinesia in patients with Parkinson's disease.
Utsumi H; Okuma Y; Kano O; Suzuki Y; Iijima M; Tomimitsu H; Hashida H; Kubo S; Suzuki M; Nanri K; Matsumura M; Murakami H; Hattori N;
Intern Med; 2013; 52(3):325-32. PubMed ID: 23370739
[TBL] [Abstract][Full Text] [Related]
11. Does the Side Onset of Parkinson's Disease Influence the Time to Develop Levodopa-Induced Dyskinesia?
Chung SJ; Yoo HS; Lee HS; Lee PH; Sohn YH
J Parkinsons Dis; 2019; 9(1):241-247. PubMed ID: 30741690
[TBL] [Abstract][Full Text] [Related]
12. Risk thresholds of levodopa dose for dyskinesia in Chinese patients with Parkinson's disease: a pilot study.
Liu G; Chen H; Su D; Wang D; Zhang M; Wang X; Wang Z; Yang Y; Jiang Y; Ma H; Feng T
Neurol Sci; 2020 Jan; 41(1):111-118. PubMed ID: 31446577
[TBL] [Abstract][Full Text] [Related]
13. Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias.
de la Fuente-Fernández R; Sossi V; Huang Z; Furtado S; Lu JQ; Calne DB; Ruth TJ; Stoessl AJ
Brain; 2004 Dec; 127(Pt 12):2747-54. PubMed ID: 15329355
[TBL] [Abstract][Full Text] [Related]
14. Effect of Subthalamic Deep Brain Stimulation on Levodopa-Induced Dyskinesia in Parkinson's Disease.
Kim JH; Chang WS; Jung HH; Chang JW
Yonsei Med J; 2015 Sep; 56(5):1316-21. PubMed ID: 26256974
[TBL] [Abstract][Full Text] [Related]
15. Optimizing long-term therapy for Parkinson disease: levodopa, dopamine agonists, and treatment-associated dyskinesia.
Stacy M; Galbreath A
Clin Neuropharmacol; 2008; 31(1):51-6. PubMed ID: 18303491
[TBL] [Abstract][Full Text] [Related]
16. Dyskinesias and levodopa therapy: why wait?
Matarazzo M; Perez-Soriano A; Stoessl AJ
J Neural Transm (Vienna); 2018 Aug; 125(8):1119-1130. PubMed ID: 29428995
[TBL] [Abstract][Full Text] [Related]
17. Levodopa-induced dyskinesia in Parkinson's disease: still no proof? A meta-analysis.
Giannakis A; Chondrogiorgi M; Tsironis C; Tatsioni A; Konitsiotis S
J Neural Transm (Vienna); 2018 Sep; 125(9):1341-1349. PubMed ID: 29352351
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of levodopa dose and magnitude of dopamine depletion as risk factors for levodopa-induced dyskinesia in a rat model of Parkinson's disease.
Putterman DB; Munhall AC; Kozell LB; Belknap JK; Johnson SW
J Pharmacol Exp Ther; 2007 Oct; 323(1):277-84. PubMed ID: 17660384
[TBL] [Abstract][Full Text] [Related]
19. An open-label, multicentre clinical trial to determine the levodopa dose-sparing capacity of pramipexole in patients with idiopathic Parkinson's disease.
Pinter MM; Rutgers AW; Hebenstreit E
J Neural Transm (Vienna); 2000; 107(11):1307-23. PubMed ID: 11145006
[TBL] [Abstract][Full Text] [Related]
20. A Placebo-Controlled Trial of AQW051 in Patients With Moderate to Severe Levodopa-Induced Dyskinesia.
Trenkwalder C; Berg D; Rascol O; Eggert K; Ceballos-Baumann A; Corvol JC; Storch A; Zhang L; Azulay JP; Broussolle E; Defebvre L; Geny C; Gostkowski M; Stocchi F; Tranchant C; Derkinderen P; Durif F; Espay AJ; Feigin A; Houeto JL; Schwarz J; Di Paolo T; Feuerbach D; Hockey HU; Jaeger J; Jakab A; Johns D; Linazasoro G; Maruff P; Rozenberg I; Sovago J; Weiss M; Gomez-Mancilla B
Mov Disord; 2016 Jul; 31(7):1049-54. PubMed ID: 26990766
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
